These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001778-21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F... 2011-04-19 due-trials
Reported results 2004-001914-15 A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudi... 2012-12-13 due-trials
Trial is partly outside EEC, and reported results 2008-006873-33 AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP... bad-data
Reported results 2008-007038-24 "Estudio piloto de una nueva combinación de maraviroc + atazanavir/ritonavir frente a atazanavir/ritonavir + emtricitabina/tenofovir para el tratamiento de pacientes con infección por VIH del tipo VIH... 2011-07-22 due-trials
Reported results 2009-010269-21 A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects. 2016-12-22 due-trials
Reported results 2009-017950-11 A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transc... 2016-12-27 due-trials
Reported results 2009-017951-87 A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen. 2015-05-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-018001-51 A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background R... 2021-02-02 bad-data
Reported results 2010-018487-16 Estudio de fase IIb para seleccionar una dosis oral diaria de GSK2248761 en combinación con tenofovir/emtricitabina o abacavir/lamivudina, en sujetos adultos infectados por el VIH-1 que no han recibid... 2011-07-04 due-trials
Reported results 2010-018532-40 A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance 2011-07-19 due-trials
Reported results 2010-020983-39 A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in ... 2015-12-03 due-trials
Reported results 2010-021785-30 A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTE... 2014-01-28 due-trials
Reported results 2010-021994-35 "Estudio multicéntrico, aleatorizado, enmascarado y controlado con placebo para evaluar la seguridad de maraviroc en combinación con otros antirretrovirales en sujetos infectados por el VIH-1 y por el... 2015-03-24 due-trials
Reported results 2011-000437-36 A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-labe... 2017-05-12 due-trials
Reported results 2011-001646-16 A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescents Patients with Integrase Resistance 2016-09-23 due-trials
Reported results 2011-003303-38 Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761 2013-02-19 due-trials
Reported results 2011-003629-86 A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini... 2016-12-26 due-trials
Reported results 2011-004435-31 An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc. 2016-08-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-005823-34 A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV... 2022-08-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-000783-29 A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regim... 2023-04-20 bad-data
Reported results 2013-003527-11 ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women. ING200336: Estudio prospectivo intervencional para evaluar la farmacocinética y segurida... 2021-09-15 due-trials
Reported results 2013-005487-26 A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 I... 2017-08-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-002111-41 A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Re... 2017-02-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-005147-40 A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or... 2023-05-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-005148-16 A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or... 2023-05-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2015-004401-17 A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who ... 2022-05-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2015-004418-95 A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plu... 2022-08-15 bad-data
Listed as ongoing, but also has a completion date and reported results 2016-000459-28 A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plu... 2022-06-29 bad-data
Ongoing, reported early 2016-001646-25 A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of V... not-yet-due
Ongoing, reported early 2016-001647-39 A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpiv... not-yet-due
Ongoing, reported early 2017-002946-62 A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Admi... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2018-000177-72 A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infecte... 2022-09-09 bad-data
Reported results 2018-002208-15 A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatm... 2020-02-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-004435-23 A Phase IIb, randomized, partially blind, active controlled, dose-range finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcripta... 2023-05-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2020-000424-19 A Phase IIIb, open-label, hybrid type III trial evaluating implementation strategies for long-acting cabotegravir plus long-acting rilpivirine every two months in HIV-1 infected, virologically suppres... 2023-03-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2020-002623-11 A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir P... 2023-04-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2021-000016-28 A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir... 2023-05-11 bad-data
Trial is outside EEC 2022-000829-24 Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1 bad-data